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Comprehensive protein-protein interaction network analysis can help reveal protein 
functions in a system-wide manner. A reliable knowledgebase of interaction networks is 
not only important for selecting the candidates for drug therapies, but also for evaluating 
the disease risk. In current interaction databases, 322579 interactions comprised of 56460 
proteins have been reported (statistical analysis from APID: Agile Protein Interaction 
DataAnalyzer; http://bioinfow.dep.usal.es/apid/index.htm). The huge datasets are 
contributed mainly by yeast -two -hybrid (Y2H) screening and affinity-purification 
followed by mass spectrometry (AP-MS). High false positive rates and failing to cover 
certain interaction categories are the limitations of these two methods. Here, we 
developed two proteomic strategies to address the limitations. First, we attempt to expand 
the dynamic of protein abundance in peptides mixtures by identifying phosphorylated 
peptides. The phosphorylation is a ubiquitous post-translation modification which is 
involved in regulating the signaling pathway and protein-protein interaction. The step of 
phosphopeptide enrichment after immunoprecipitation was employed as the second 
purification to reduce the complexity of the samples. With this approach, the sample 
complexity was significantly reduced because most of the unmodified peptides were 
removed after the phosphopeptide enrichment. In this simplified sample, the number of 
many high abundant proteins and peptides identified, such as ribosomal proteins, was 
significantly reduced, resulting in improved identification of Plk1 interacting proteins. 
We also applied this approach to the PRMT5 network, in which few phosphorylation
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events have been reported. In the PRMT5 complex, we identified multiple 
phosphoproteins that were not identified in conventional AP-MS, which provided us with 
complementary candidates list for follow-up investigation.   
For the second strategy, we developed a trifunctional chemical reagent to study the 
virus-host interactome. The reagent contains a maleimide group for labeling virus surface 
proteins, a biotin tag for capturing the virus particle, and a TAMRA fluorescence 
molecule in the first generation reagent for method development. The maleimide group 
targets the free thiols on Sindbis virus surface proteins is the critical step to process the 
virus modification by the trifunctional reagent. In this study, we successfully captured the 
labeled-virus by streptavidin agarose beads from the infected cells, and several identified 
host proteins were known to involve in the virus infection pathways which means the 
labeled-viruses still maintain the pathogenic property. The method will further replace the 
TAMRA fluorescent beacon to a UV-activated photocrosslinker for “fixing” the virus 
binding partners after several harsh wash conditions to remove the non-specific binding 
protein. We expect the second generation reagent should result in more accurate 
identification of host proteins involved in virus infection. 
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    The term of “interactome” was originally coined by Bernard Jacq in 1999 [1]. 
Interactome usually means the physical interaction between two proteins, but it can also 
be considered as indirect interactions among genes. Unlike the signaling cascades, 
interacome represents systematically interlinked networks in cells. The importance of 
mapping an interaction network includes the identification of the best candidates for 
disease therapy development and evaluation of the disease risk. In this decade, many 
online interactome databases have become available, and the accumulation of 
information is at an increasing pace. The statistical analysis from BioGRID 
(http://wiki.thebiogrid.org/doku.php/statistics) indicates that the knowledgebase of 
non-redundant physical interactions in all organisms have increased from 88028 links 
comprised of 22691 proteins in 2006 to 346181 links comprised of 53603 proteins 
currently. The major contribution to the data comes from Homo sapien and 
Saccharomyces cerevisiae interactome studies, which contribute 267427 and 85631 
non-redundant interactions from 173915 and 6631 proteins, respectively. However, 
multiple databases aim to systematically collect the entire set of interactions from 
different organisms, but they do not put sufficient effort in filtering out the unreliable 
results. The data from independent publications have little overlap to determine which 
interactions are correct [2]. The low overlap of datasets is caused by either transient 
interactions or ones that occur only under specific stimulation conditions or subcellular 
localization. The methods and experimental conditions can also influence the 
identification of interacting proteins. Several studies have focused on the quality 
improvement of interactome analysis by either building up a scoring database to filter the 
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interactions from different interactome databases [3, 4], or by combining the 3D structure 
and the binary interaction datasets to visualize the interaction interface [5]. As the simple 
accumulation of interaction numbers is no longer with the aim of most researchers. 
Instead, a high-quality examination of the interactome network is becoming more 
important for the systematic protein-protein interaction study.  
 
1.2 Methods for interactome study 
 
    There are two main approaches for detecting protein interactions: The “binary 
approach” means the analysis of direct physical interaction between protein pairs. The 
other method is “complex approach”, which examines the interactions among groups of 
proteins. The yeast-two-hybrid system (Y2H) is the most frequently used binary approach. 
It is based on coupling of the bait and prey proteins to the DNA binding and activation 
domains of eukaryotic transcriptional activator, respectively. If the two proteins interact, 
the transcriptional activator is reconstituted and turns on the reporter gene expression [6]. 
Although the Y2H provides large-scale screening for binary interactions studies, the 
interactions themselves are not under the physiological environment. A positive 
interaction in Y2H system does not necessarily represent that the interaction will occur in 
cells or whether the interaction has biological functions. Fluorescence Resonance Energy 
Transfer (FRET) and Bimolecular Fluorescence Complementation (BiFC) are the 
fluorescence-based methods for binary interaction studies in living cells [7, 8]. However, 
these two methods are usually used to validate the relation between specific protein 
candidates, not as a discovery tool.  
The main method of “complex approach” is affinity purification (AP) followed by 
mass spectrometry (MS). The AP-MS strategy detects protein-protein interactions by 
using antibodies targeting the endogenous bait protein or epitope-tagged targets. The 
general procedure of AP-MS includes the immobilization of a ligand (antibody) to a solid 
phase (e.g. agarose or magnetic beads), and to capture the target protein and its 
interacting partners. The co-purified complex can be analyzed by mass spectrometry 
analysis [9]. Since the recent advances in instrumentation have led to high sensitivity and 
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faster duty cycles of mass spectrometry, the AP-MS has been gaining momentum over 
the past decade as a major tool for protein-protein interaction studies. However, the high 
false positive rate from background contaminants is the major problem of AP-MS 
strategy. The phenomenon discussed in more detail in the section 1.3.  
 
1.3 The coverage, accuracy and limitations of interactome 
 
    As discussed in section 1.1, building up high quality interaction datasets is the main 
aim for current interactome studies. The quality of interaction data needs to be validated 
by both coverage and accuracy [10]. The statistical analysis of data from APID (Agile 
Protein Interaction DataAnalyzer; http://bioinfow.dep.usal.es/apid/index.htm) shows that 
there is a very small overlap between the total 80032 human protein-protein interactions 
from 6 primary interactome databases (IntAct, HPRD, BioGRID, BIND, MINT and DIP) 
[11]. The low coverage by datasets is likely due to individual experimental method for 
detecting interactions that have not reached its full potential. For example, some of the 
transmembrane transporters and receptors are not easily identified in affinity-purified 
complexes because these types of proteins need to be purified by specialized procedures.  
In Saccharomyces cerevisiae, more than 30,000 potential interactions among ~6,000 
proteins have been estimated [12], but already more than 100,000 binary interactions 
between yeast proteins are currently listed in the databases (statistics from APID: Agile 
Protein Interaction DataAnalyzer; http://bioinfow.dep.usal.es/apid/index.htm). The 
observation indicates that many of the experimental interactions in these datasets are 
probably false positives. Low accuracy can be addressed by using different methods to 
get complementary data because each detection method has its specific weaknesses. For 
instance, the original Y2H system is used to study the interaction of particular protein 
pairs, but this method cannot be used for the post-translational modifications-based or 
cofactor-based interactions [13]. Not only the potential for such false negative results, but 
also for the false positive data by auto-activating transcription of some bait proteins are 
the disadvantages of Y2H system [14]. The high – throughput AP-MS contributes the 
majority of interaction datasets in this decade. AP-MS can detect complexes in 
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physiological environment, but a number of drawbacks influence the accuracy of this 
method. First, the high false positive rate caused by high abundance of background 
proteins is the major limitation. The concentration of proteins in human can be dynamic 
[15, 16], and after trypsin digestion, high abundant proteins produce very complicated 
peptide mixtures. Moreover, some exogenous proteins from careless sample preparation, 
such as keratins, are also considered as abundant contaminants. Current mass 
spectrometry dynamic range of detection is between 1,000 -10,000 [17]. Highly abundant 
proteins dominate the redundant identifications while the low abundance proteins are 
inadvertently excluded from the results. Second, some transient or loosely-associated 
interaction partners may be lost during the purification and produce false negative results. 
Third, some of the interactions may not be detectable under the tested conditions, thus 
some synchronization at a specific cell cycle stage or ligand stimulation experiments are 
needed. Lastly, a tag on the baits proteins may interfere with the complex formation and 
introduce bias during detection.  
In this study, we developed new strategies to address the limitations of AP-MS by 
using phosphopeptides identification to increase the sensitivity to detect low abundant 
proteins, and chemical modification of Sindbis virus surface proteins to study specific 
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CHAPTER 2. A NEW STRATEGY TO REVEAL PROTEIN CANDIDATES IN 







2.1.1 The post-translational modifications 
The covalent post-translational modification (PTM) on proteins generates diversity 
in eukaryotic proteome. The reversible process by specific enzyme-substrate mechanism 
alters the protein properties by adding chemical groups to the side chain of residues. The 
modified proteins change their properties to response the cellular messages, and then the 
destiny of these proteins are led to different ways. Due to the improvement of detection 
methods, there are more than 200 PTMs have been found [1] and the statistics of major 
PTMs in PhosphositePlus   
(http://www.phosphosite.org/homeAction.do) is shown in Figure 2.1A. Some of the 
modifications change the protein structure for protein maturation and proper folding, such 
as glycosylation and disulfide bond. Acetylation and methylation are known in regulating 
the gene expression and histone-DNA or protein-protein interactions [2, 3]. Some 
proteins are modified by the covalent attachment of another protein, such as 
ubiquitination. The wide-spread phosphorylation is more highly transient and dynamic in 
response to extracellular and intracellular signaling. Furthermore, different PTMs can 
cooperate in cellular response or compete against others on the same residue to regulate 
the function of modified proteins. The crosstalk of PTMs contributes the complexity of 
cellular microenvironment [4]. Thus, identification of proteins with PTMs is a potential 





2.1.2 Phosphorylation and protein-protein interaction 
Phosphorylation is one of the most wide-spread and early descripted modifications 
in eukaryotic proteins [5, 6]. In human proteome, there are 74% of proteins reported to be 
phosphorylated at particular moment (Figure 2.1B; statistics from UniProt and 
PhosphoSitePlus
®
). Reversible phosphorylation is regulated by kinases and 
phosphatases. In eukaryotes, 1.5-2% of protein encoding genes are the protein kinase 
families [7]. The protein kinase introduces a phosphoryl group on residues such as serine, 
threonine, and tyrosine, and adds negative charges at the physiological pH to disturb the 
protein conformation. The structure alternation affects the protein-protein interaction and 
the enzyme activity [8]. The major role of the phosphorylation in protein-protein 
interaction is to create docking sites for proteins binding [9]. For example, polo-like 
kinase 1 (Plk1) is inactivated by the intramolecular interaction between polo-box domain 
and kinase domain. The substrate of Plk1 is prior phosphorylated by a priming kinase (e.g. 
Cdk1), and then binds to the polo-box domain to release Plk1 auto-inhibition. The relief 
of auto-inhibition results in Plk1 activity stimulation and phosphorylates downstream 
substrates in the signaling pathway [10, 11].  
Due to the ubiquitous property and the roles in protein-protein interaction, 
phosphorylation becomes a potential aspect for interactome study. In addition, methods 
for phosphopeptide enrichment are relatively specific nowadays, and we can routinely 
analyze the phosphopeptides by mass spectrometry. Without the phosphopeptide 
enrichment, low occurrence and the negative charge of phosphoryl group make the 
peptides difficult to be detected among all non-phosphorylated peptides [12]. The 
phosphopeptide enrichment facilitates the phosphopeptides identification in mass 
spectrometry by removing many non-phosphopeptides. Concurrently, only 
phosphopeptides are isolated from each protein leading to significantly reducing the 
complexity of the immunoprecipitation sample. Many phosphorylated proteins are 
potentially low abundant, and they can be easily concealed in high background of 
abundant proteins, such as ribosomal proteins, cytoskeleton proteins and contaminating 
keratins. We reason that the coverage and the sensitivity to identify potential candidates 
can be increased after removing the unmodified peptides. Thus, my hypothesis is that the 
9 
 
ubiquitous phosphorylation can be used to differentiate phosphorylated peptides from 
unmodified peptides, to simplify the sample complexity for mass spectrometry analysis, 
and to identify complementary interacting candidates in phosphopeptides enriched 
sample. 
 
2.1.3 Models in this study 
Here, we studied the polo-like kinase 1 (Plk1) and protein arginine 
methyltransferase 5 (PRMT5) interaction network. Plk1 network is known to involve in 
many phosphorylation regulation events. As a kinase, Plk1 itself is not only activated by 
other kinases, but also regulates downstream substrates by phosphorylation. The highly 
phosphorylation network leads Plk1 to an ideal positive model for us to test our 
hypothesis. To enrich the phosphopeptides, we used the soluble polymer-based metal ion 
affinity capture (PolyMAC) [13] with high selectivity and sensitivity in this study. The 
experimental design is shown in Figure 2.2. Briefly, the protein complex 
immunoprecipitation was achieved with affinity tag and then subjected to different 
procedures. In one procedure, the purified protein complex was directly analyzed by 
LC-MS/MS (conventional IP-MS), but in another procedure, digested peptides was 
treated with PolyMAC before LC-MS/MS analysis. The mass spectrometry results were 
compared using known interaction partners and typical highly abundant contaminants 
identified in each strategy.  
To generalize the strategy, we also applied the strategy to the PRMT5 protein 
complex in which few phosphorylation studies have been reported. We hypothesize that 
the wide-spread phosphorylation gives us a high chance to discover novel interacting 
candidates of PRMT5 through the identification of phosphorylated peptides. Those 
candidates could be a transient interaction partner or a low abundant protein which are 
masked by highly abundant proteins in the complex. The purpose of the method in this 
type of model is to reveal complementary interacting candidates to those identified in a 




2.2 Materials and Methods 
 
2.2.1 Cell culture and plasmid transfection 
HEK293T cells were grown in DMEM with 10% fetal bovine serum and antibiotics 
at 37°C and 5% CO2. The X-tremeGENE®  9 DNA transfection reagent (Roche 
Diagnostics) was used for transiently transfecting wild-type Plk1-FLAG plasmid (gift 
from Xiaoqi Liu’s lab) to cells. After 24 hours transfection, the cells were synchronized 
to G2/M phase by 1x Nocodazole. LnCap cells were grown in RPMI with 10% fetal 
bovine serum, sodium pyruvate and antibiotics at 37°C and 5% CO2. The Lipofectamine 
2000 transfection reagent (Life Technologies) was used for transiently transfecting 
myc-PRMT5 plasmid (gift from Chang-Deng Hu’s lab) to cells. 
 
2.2.2 Cell extracts 
Transfected cells were harvested by trypsin and washed with sterile PBS. Cell pellet 
was resuspended in lysis buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP40] 
supplemented with 1x protease inhibitor (Tablet from Roche), 1x phosphatase inhibitor 
cocktail (Sigma), 1 mM sodium orthovanadate, and 10 mM sodium floride. Cells were 
lysed by probe sonication on ice twice with a 20 second pulse and 10 second interval. 
The supernatant containing soluble proteins was collected after centrifugation at 14000 
rpm for 10 min. The protein concentration was estimated by using BCA protein assay 
(Pierce Biotechnology, Inc.).  
 
2.2.3 Immunoprecipitation 
wt-Plk1-FLAG cell lysate was immunoprecipitated with Anti-FLAG®  M2 Magnetic 
Beads (Sigma), incubated at 4°C on rotator for 4 hours, and further washed with 20x bed 
volume of lysis buffer. The complex was eluted by 100 mM Triethylamine (TEA, pH 
11.6) or 1% Trifluoroacetic acid. The elutions were dried in a SpeedVac and store at 
-80°C for further use.  
    Myc-PRMT5 cell lysate was overnight incubated with 250:1 (v/v) mouse 
myc-tag mAb (Cell Signaling). Protein G agarose beads (Genescript) were added, and 
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incubated at 4°C on rotator for 1 hour, further washed with 20x bed volume of lysis 
buffer. The complex was eluted by 100 mM Triethylamine (TEA, pH11.6). The elution 
was dried in a SpeedVac and store at -80°C for further use.  
 
2.2.4 Reduction, alkylation, trypsin digestion and Nu-Tip®  C18 desalting 
Alpha-casein was added into the elution for phosphopeptides internal control (lysate: 
casein = 10000: 1 w/w). The eluted complex was reduced in 50 mM ammonium 
bicarbonate containing 5 mM dithiothreitol for 30 min at 50 °C. The proteins were further 
alkylated in 15 mM iodoacetamide for 1 hour in the dark at room temperature and 
digested with 0.5 μg proteomics grade trypsin (Sigma) in a total volume of 300 μl 
solution containing 50 mM ammonium bicarbonate (pH 8.3) at 37℃ overnight. The 
tryptic sample solution was acidified by Trifluoroacetic acid (TFA) to pH ~3. The 
Nu-Tip®  C18 (Glygen Corp.) were prewetted by pipetting three times with 100% 
Acetonitrile (ACN). The tips were equilibrated by pipetting ten times with 0.1% TFA. 
The peptides were bound to Nu-Tip by fully pipetting to a dead stop and aspirating 
sample 20 cycles, and then washed tips with 0.1% TFA for 15 cycles. Fifty microliters of 
0.1%TFA/80% ACN were aspirated into a new sterile centrifuge tubes and pipetted 20 
times to elute peptides. The desalting peptides were dried in a SpeedVac. 
 
2.2.5 PolyMAC phosphopeptide enrichment 
Tryptic peptides were split into two aliquots. One of the aliquots was dried in a 
SpeedVac, and further resuspended by loading buffer (100 mM glycolic acid, 1% 
trifluoroacetic acid, 50% acetonitrile). The peptide mixture was incubated with the 
PolyMAC and shake vigorously for 5 minutes at ~900 rpm. The capturing buffer (300 
mM HEPES, pH 7.7) was added to the mixture to adjust the final pH above 6.3 before 
transferring the solution into the magnetic capture beads. The mixture was gently agitated 
for 10 minutes at ~900 rpm. The magnetic beads were washed once with loading buffer 
and twice with washing buffer (100 mM acetic acid, 1% trifluoroacetic acid, 80% 
acetonitrile). The phosphopeptides were eluted by incubating the magnetic beads twice 
with 400 mM ammonium hydroxide solution containing 30% acetonenitrile for 5 min. 
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The elution was collected and dried in a SpeedVac. The other aliquot of peptides were 
purified by Nu-Tip®  C18 (Glygen Corp.). 
 
2.2.6 Western Blotting 
The eluted proteins and input (total lysate) were separated by SDS-PAGE and 
transferred onto PVDF membranes. Membrane was incubated in blocking buffer (10% 
BSA in TBS with 0.05% Tween-20) for 1 h at room temperature and then incubated in 
blocking buffer containing the 1:1000 dilution of rabblt anti-FLAG antibody (Cell 
Signaling Technologies) or mouse myc-tag mAb (Cell Signaling Technologies) at 4°C 
overnight. The membranes were then washed three times in TBS with 0.05% Tween-20 
for 5min. The membranes were further incubated with horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse IgG antibodies (Cell signaling Technologies) for 1 hour at room 
temperature. After several washes, the blots were developed with HyGlo 
chemiluminescence reagent (Denville scientific, Metuchen, NJ). 
 
2.2.7 Mass spectrometry 
The resulting peptides were resuspended in a solution containing 0.25% formic acid 
(v/v) and analyzed using an Easy-nLC1000 (Thermo Scientific, San Jose, CA) coupled to 
a hybrid mass spectrometer (LTQ-Orbitrap-Velos; Thermo Scientific, San Jose, CA). The 
peptides were applied to an analytical column (75 μm x 30 cm, 2.2μm, 
ProntoPEARL-120-2.2-C18AQ beads (BISCHOFF chromatography) at ~200 nl/min, and 
eluted using a gradient that ran from 5 to 30% of acetonitrile (0.1% formic acid) over 60 
minutes. The LTQ-Orbitrap-Velos MS was operated in a data-dependent mode to switch 
between MS and MS2 acquisitions. The MS survey scans were acquired over a full m/z 
range of 300-2000 by the detector. The 20 most intense precursor ions were sequentially 
isolated and subjected to collision induced dissociation (CID) in the linear ion trap. The 
general mass spectrometric conditions were: ESI voltage - 2.8 kV; transfer capillary 





2.2.8 Computational analysis of mass spectra 
The Excalibur MS raw files were searched against a human database using 
SEQUEST algorithm on Proteome Discoverer (version 1.3, Thermo Fisher). The search 
parameters included a peptide mass tolerance of 10 ppm and the MS/MS tolerance of 0.8 
Da. In the residues modification, the variable modifications were set to +15.9949Da for 
the potential oxidation of methionine and to +79.996 Da on serine, threonine, or tyrosine 
for the identification of phosphorylation. The static modification of cysteine residues of 
+57.0214Da was set due to the alkylation by iodoacetamide. Searches were performed 
with full tryptic digestion and allowed a maximum of two missed cleavages on the 
peptides. False discovery rates (FDR) were set to 1% for each analysis. Phosphorylation 
site localization from CID spectra was determined by PhosphoRS on Proteome 






2.3.1 PLK1 interaction complex analysis: Analysis of Plk1-FLAG expression in 
293T cells and the immunoprecipitation with anti-FLAG magnetic beads 
Human Plk1 is a cell cycle regulating kinase and plays a key role in spindle 
assembly, centrosome maturation, and the mitosis entry and exit progression with many 
interacting proteins [11, 14]. The expression level of Plk1 reaches its peak value in 
mitotic stage [15]. Here, 293T cells with over-expressed Plk1-FLAG were synchronized 
at mitosis with Nocodazole treatment. Plk1 interacting complex was immunoprecipitated 
by anti-FLAG magnetic beads. The efficient elution condition has been tested and shown 
in Figure 2.3. Both 100mM TEA and 1% TFA can efficiently elute the bait Plk1-FLAG 
from anti-FLAG magnetic beads. Thus, the optimum elution was performed by the 
combination of TEA and TFA. The Western blot results of Plk1 protein expression and 
elution are shown in Figure 2.4. The fusion protein bands are located at the predicted 
~70KDa. 
 
2.3.2 MS analysis of Plk1-FLAG complexes 
In the Plk1-FLAG immunoprecipitation experiments, a total of 543 proteins (2359 
peptides) and 258 proteins (598peptides) against human IPI database were identified 
from conventional IP and IP-PolyMAC, respectively (Figure 2.5A). For the internal 
control of alpha-casein, we identified 15 unique peptides with 62.15% and 25.68% 
sequence coverage from alpha-S1-casein and alpha-S2-casein in IP-only, respectively. 
There were only 3 unique phosphorylation sites identified in IP-only. Ten unique 
peptides with 24.77% of sequence coverage in alpha-casein S1 and 13.96% of sequence 
coverage in alpha-casein S2 were identified after PolyMAC enrichment. Although the 
coverage of identified alpha-casein sequence was reduced, the ratio of identified 
phosphopeptides to total peptides was increased from 33.3% in IP-only to 94% in 
IP-PolyMAC which means the PolyMAC enrichment is efficient.  
After the removal of protein identified in the negative control, there were 11 and 14 
known Plk1 interacting proteins identified by conventional IP-MS and IP-PolyMAC-MS, 
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respectively. In these 17 identified Plk1 interaction proteins, 8 proteins (HSP90, ERCC6L, 
P53BP1, GWL, MCM2, SLX4, RanGAP1, WEE1) were listed in both of the two 
strategies, 3 proteins (14-3-3, Vimentin, MCM7) were unique in conventional IP-MS data, 
and 6 proteins (CDK1, FOXO1, FOXM1, PRC1, BUB1β, MLF1IP) were only identified 
in IP-PolyMAC (Figure 2.5A and Table 2.1). None of the known interaction proteins 
were identified in negative controls (Figure 2.5B and C).  
 
2.3.3 Data analysis of the Plk1 interacting proteins and the abundant non-specific 
proteins 
At the protein level, the identified protein number was reduced ~53% from 543 
proteins in IP-only to 258 proteins in IP-PolyMAC (Figure 2.6A). However, the ratio of 
known Plk1 interactors to total identified proteins in IP-PolyMAC (5.4%) was higher 
than IP-only (2.0%) (Figure 2.6B). At the peptide level, PolyMAC can reduce ~75% of 
peptides (from 2359 peptides in IP-only to 598 peptides in IP-PolyMAC) (Figure 2.6A), 
but the ratio of peptides from known Plk1 interactors was increased from 3.4% in IP-only 
to 8.5% in IP-PolyMAC (Figure 2.6B). 
In proteomics study, the high abundant proteins such as ribosomal proteins, keratins 
and heat shock proteins are commonly identified in the immunoprecipitation “black list”. 
Here we identified fewer keratins, heat shock proteins and ribosomal proteins in 
IP-PolyMAC than IP-only, especially the number of ribosomal proteins were reduced 
~82.5% (Figure 2.7A). The peptides from these proteins were significantly reduced after 
PolyMAC treatment (Figure 2.7B).  
 
2.3.4 PRMT5 interaction complex analysis: Analysis of myc-PRMT5 expression in 
LnCap cells 
The function of Protein arginine methyltransferase 5 (PRMT5) is to modify 
chromatin proteins and non-chromatin proteins in several cellular progressions. PRMT5 
forms a complex termed the “methylosome” with its cofactor WD repeat protein 
(MEP50/WDR77/p44) and different transcriptional regulators [16]. The methylation of 
H2A, H4 and H3 [17-19] at specific arginine residues is implicated in gene silencing [20]. 
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PRMT5 plays an important role in tumorigenesis and the overexpression of PRMT5 
facilitates tumor growth by repressing tumor suppression genes [20-22].  
The function of PRMT5 methylation is also involved in cell signaling and 
transcriptional modification. The methylation of EGFR by PRMT5 leads to EGFR 
phosphorylation at tyrosine1197, which then affects ERK signaling and cellular 
proliferation [23]. The mutant JAK2 in myeloproliferative disease has been reported to 
disrupt the interaction between PRMT5 and its cofactor MEP50 by JAK2V617F-mediated 
PRMT5 phosphorylation [24]. PRMT5 associates with MEP50 and pICln, and catalyzes 
the methylation of Sm proteins to assembly the small nuclear ribonucleoprotein (SnRNP) 
in spliceosome for splicing the cellular pre-mRNA [25].  
Myc-PRMT5 was overexpressed in LnCap prostate cancer cell line and the 
transfection was examined by Western blot with mouse anti-myc antibody and rabbit 
anti-PRMT5 antibody (Figure 2.8). Non-transfected LnCap cells were used as a negative 
control. Myc-PRMT5 was detected at MW ~75KDa in the blot with anti-myc antibody. 
Endogenous PRMT5 has lower MW than myc-PRMT5 in the blot with anti-PRMT5 
antibody. Equivalent protein loading on the gel was confirmed by the level of GAPDH. 
 
2.3.5 Western blot analysis of immunoprecipitation with anti-myc antibody  
PRMT5 complex was immunoprecipitated with anti-myc antibody and captured on 
the protein G agarose beads. The efficient elution condition has been tested by a series of 
elution buffers. As demonstrated in Figure 2.9, the complex was eluted efficiently by 
100mM TEA (pH11.6), and additional myc-PRMT5 was not detected in subsequent 
elutions done by incubating with 1% TFA or by boiling in SDS sample buffer. Thus, the 
optimum elution was performed by TEA. The western blot result of myc-PRMT5 
immunoprecipitation with anti-myc antibody is shown in Figure 2.10. The myc-PRMT5 
was clearly detected in immunoprecipitation of transfected LnCap cells but not in 
negative control. Equivalent total lysates for immunoprecipitation were confirmed by the 





2.3.6 MS analysis of PRMT5 complexes 
In myc-PRMT5 immunoprecipitation experiment, after the removal of protein 
identified in the negative control, there were 105 proteins identified by conventional 
IP-MS and 28 proteins by IP-PolyMAC. Several PRMT5 interacting proteins including 
MEP50, pICln, smD1, smD2, smD3, SNRPE, HSP90 [26], NFkB [27] and SERPB1[28] 
were identified in the IP sample indicating overall immunoprecipitation was successful 
(Figure 2.11). As expected due to low phosphorylation events in the complex, PolyMAC 
treatment significantly reduced identified proteins and the unique protein list 
complements to conventional IP strategy. The overlapped proteins which identified by 
both strategies were the bait PRMT5 and its regulating partner pICln. A total of 26 
potentially novel candidates were identified after PolyMAC treatment. With 
IP-PolyMAC strategy, PRMT5, pICln and HSP90 known to be involved in PRMT5 
network were identified with phosphorylation sites at ser15 and ser16 in PRMT5, ser102 
in pICln and ser177 in HSP90B2. The phosphorylation sites in pICln and HSP90B2 were 
previously reported by unrelated large-scale phosphoproteome screening [29-31], but 
their functions and mechanisms have not yet been reported. Reports of PRMT5 
phosphorylation are extremely limited and the two phosphorylation sites identified in 






2.4.1 The identified interacting partners coordinate mitotic progression with Plk1 
    The 14 Plk1 interacting partners in IP-PolyMAC were known to be involved in 
coordinating mitotic progression with Plk1. The proteins involved in kinetochore 
localization are RanGAP1 [32] and BUB1β [33]. PRC1 [34] which is a protein regulated 
by Plk1 to prevent the premature of midzone formation before cytokinesis. CDK1 is a 
priming kinase in mitosis to phosphorylate several substrates and form a positive 
feedback loop to regulate the mitosis stage [35-37]. MLF1IP [38] help the chromosome 
segregation, and FOXO1[35, 36], FOXM1 [39] and WEE1 [40] control the entry of 
mitosis. MCM2-MCM7 complex coordinates DNA replication with Plk1 [41]. SLX4 [42, 
43] and ERCC6L [44] (also named PICH) are involved in DNA repair. HSP90 [45] 
regulates the metaphase-anaphase transition, and GWL [46] coordinates the checkpoint 
recovery in a Plk1-dependnet manner. In addition, Plk1 has a potential role in inhibiting 
the function of P53BP1 in tumorigenesis [47].  
    The polo-box domain of Plk1 recognizes Ser-[pSer/pThr]-Pro/X motif on polo 
kinase substrates [48]. We extracted the significant motifs from the identified peptides of 
the 14 known Plk1 interaction proteins in IP-PolyMAC by motif-x program 
(http://motif-x.med.harvard.edu/motif-x.html), the motif logo is consistent with a serine 
at the -1 position and a strongly selection for proline at the +1 position (Fig 2.12).  
 
2.4.2 PolyMAC treatment provides an efficient way to simplify the affinity 
capture-mass spectrometry data for candidate selection 
While hundreds of proteins in an immunoprecipitation sample can be detected in a 
single mass spectrometry experiment, selecting interesting candidates for validation and 
in-depth biological characterization is a daunting task. Abundant proteins usually 
dominate the detection and hamper the MS sensitivity and coverage in a typical LC-MS 
analysis, which makes it even more difficult to choose interesting candidates for 
validation. The IP-PolyMAC distinguishes itself from the conventional IP strategy by the 
second purification via phosphopeptide enrichment. We reason that phosphorylation can 
be used as a filter to simplify the immunoprecipitation sample, and address the major 
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drawback of highly abundant contaminants in conventional IP-MS. Several benefits were 
gained by IP-PolyMAC strategy. First, most of the unmodified peptides were removed, 
especially the peptides from highly abundant proteins such as ribosomal proteins and 
contaminating keratins. The phosphopeptide enrichment step efficiently reduced the high 
background of dominating proteins in MS analysis. Second, the number of identified 
proteins was significantly reduced after PolyMAC treatment to facilitate researchers to 
choose important candidates for follow-up experiments. Third, the enrichment of 
phosphopeptides in IP sample yields the modification sites that have potential roles for 
future investigation. In summary, suppressing background abundant proteins via 
phosphopeptide enrichment, our IP-PolyMAC strategy provided high sensitivity and 
specificity of result in Plk1 network.  
 
2.4.3 Summary and future directions in analysis of the Plk1 complex 
Protein phosphorylation plays a pivotal role in regulating protein-protein interaction. 
Dysfunctional protein-protein interactions lead to several diseases such as human 
malignancies. However, current methods for interactome study present multiple 
drawbacks that prevent researchers to understand the network and identify important 
interacting proteins. In this project, we have illustrated a strategy with tandem 
purification steps, including immunoprecipitation and phosphopeptide enrichment for 
screening the interacting partners. The addition of the second purification by PolyMAC 
significantly reduces the number of abundant proteins and reveals novel proteins in the 
complex. These included stathmin, a protein involved in tubulin dynamics; NFkB, 
Mre11A, MDC1 and HMGA1, the proteins involved in DNA damage repairing; and 
ACAA1, EIF5B and PRKAR2A which are related to metabolism in the Plk1 complex 
(Table 2.3). Stathmin is a particularly interesting identification because in 
stathmin-depleted cells, recruitment of Plk1 to the centrosome is delayed, and the 
activation of Aurora A, which is an upstream kinase of Plk1, is reduced [49]. We 
identified two phosphorylation sites at Ser16 and Ser25 on stathmin. Ser16 
phosphorylation was known in response to increased intracellular calcium, and Ser25 was 
reported to be the target site for the mitogen-activated protein (MAP) kinase family [50]. 
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Mutation of Ser16 and Ser63 on stathmin abolished Aurora A phosphorylation [49]. 
While stathmin depletion influences the activities of Plk1 and Aurora A at mitotic entry, 
the precise mechanism regulating these enzymes is not yet clear. We hypothesize that the 
other eight candidate proteins found in our study may also play essential roles via their 
identified phosphorylation sites to regulate cellular functions with Plk1.  
 
 
2.4.4 IP-PolyMAC strategy provides a complementary approach to reveal potential 
candidates in PRMT5 network 
    The two strategies by conventional IP and IP-PolyMAC provided complementary 
protein lists in PRMT5 complex. The overlapping proteins in these two approaches were 
the bait PRMT5 and its regulating partner, pICln. With IP-PolyMAC strategy, only 28 
proteins were identified after removing the proteins in the negative control. The low 
number of identified proteins is as expected, because the PRMT5 complex, which few 
phosphorylation events have been reported, is carefully selected as a model system to test 
our strategy. We significantly reduced the number of identified proteins from hundreds to 
less than 30. The simplified candidate list allows researchers to focus and select 
interested proteins for future test. Moreover, the phosphorylation sites that we identified 
can also be used for studies of mechanisms on particular phosphorylated residues by 
mutagenesis.   
 
2.4.5 Future direction in PRMT5 complex 
Beside the Plk1 complex, we have tried to investigate the anaphase –promoting 
complex (APC) and the proteasome complex for testing our hypothesis; however, the two 
complexes are too stable and well-defined to have better results with IP-PolyMAC 
strategy. The PRMT5 complex is a challenge model because more transient interactions 
events than above stable complexes in PRMT5 network. The difficulty of testing a 
transient interaction model is the random patterns of the identified proteins in each 
immunoprecipitation experiment. Because the low number of identified proteins in this 
study is the outcome of a single experiment, it is difficult to define the 26 unique 
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identified proteins in IP-PolyMAC are all the PRMT5 interacting proteins. We are trying 
to complete the biological and technical replications in this model and to get a more 
convincible protein list for future investigation. However, in this study, two interesting 
candidate proteins in IP-PolyMAC were selected by our collaborator for investigation, 
the mitochondria uncoupling proteins 2, UCP2; and the histone-lysine 
N-methyltransferase SETD1B (Table 2.3).  
    UCP2 is a mitochondrial transporter protein which known to be involved in 
regulation of energy expenditure, obesity [51] and aging [52]. SETD1B is a histone 
methyltransferase which associates with DNA methyltransferases DNMT3A to promote 
the silence of tumor suppressor gene [53]. The interaction evidence of UPC2, SETD1B 
and PRMT5 has not yet been reported. In this study, several novel phosphorylation sites 
in UCP2 and SETD1B were identified by IP-PolyMAC, which may reveal important 
functions of the PRMT5 complex in the regulation of energy expenditure or the 
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Figure 2.1 Calculations of posttranslational modifications in PhosphoSitePlus
®
 and 
the phosphoproteins in human proteome. (A) The percentage of each PTM in 
PhosphoSitePlus
®  
database. (B) The human phosphoproteins from Uniprot and 
PhosphositePlus
®
































   
Figure 2.2 Work flow of the experimental design. (Left) In the Plk1 network study, 
wt-Plk1-FLAG was overexpressed in HEK 293T cells and the cells were treated with 
Nocodazole to arrest in mitosis. Anti-FLAG magnetic beads were used to capture the 
Plk1 complex. (Right) In the PRMT5 network study, myc-PRMT5 was overexpressed in 
LnCap cells and the PRMT5 complex was captured by anti-myc antibody and protein G 
agarose beads. The critical step is the second purification of immunoprecipitated complex 
by phosphopeptide enrichment via PolyMAC (IP-PolyMAC). The procedure of 
immunoprecipitation and PolyMAC phosphopeptide enrichement are described in detail 







Figure 2.3 Western blotting analysis of the Plk1-FLAG affinity purification with 
different elution conditions. Wt-Plk1-FLAG cell lysate was immunoprecipitated with 
Anti-FLAG®  M2 magnetic beads (Sigma), further washed with lysis buffer three times 
and eluted with 100 mM Triethylamine (TEA), pH 11.6 or 1% Trifluoroacetic acid (TFA). 
The loading amount of each sample was 1% of total volume. Plk1-FLAG protein was 
detected by Western blot with anti-FLAG antibody. The magnetic beads were boiled by 
SDS sample buffer after TEA or TFA elution (SDS re-elution) to examine the elution 
efficiencies by TEA and TFA. (-) indicates the negative control which was 







Figure 2.4 Western blotting analysis of the Plk1-FLAG affinity purification. 293T 
cells overexpress Plk1-FLAG were synchronized at G2/M phase by Nocodazole, 
precipitated with anti-FLAG magnetic beads and visualized by Western blot with mouse 
anti-FLAG antibody. The loading amount of each sample is indicated by the percentage 















Figure 2.5 Summary of Plk1 interaction proteins identified by conventional IP and 
IP-PolyMAC strategies. (A) Fourteen of 258 identified proteins in IP-PolyMAC were 
known Plk1 interacting proteins and six of the 14 proteins (CDK1, FOXO1, FOXM1, 
PRC1, BUB1β and MLF1IP) were uniquely identified in IP-PolyMAC. Eleven of 543 
identified proteins in IP-PolyMAC were known Plk1 interactors, but only 3 proteins 
(14-3-3, Vimentin and MCM7) were unique in IP-Only. Eight known interaction proteins 
(HSP90, ERCC6L, P53BP1, GWL, MCM2, SLX4, WEE1 and RANGAP1) were listed in 
both of the two strategies. The overlapping proteins with (B) negative control have been 









Figure 2.6 Data analysis of known Plk1 interactors in total number of protein and 
peptides. (A) The IP-PolyMAC strategy (Grey bar) reduced the candidate list at both 
protein and peptide levels. ~53% and ~75% of total protein and peptides were reduced 
after PolyMAC treatment; (B) The ratio of known Plk1 interacting proteins in the 








































Figure 2.7 Comparison of three groups of high abundant proteins, keratin (KRT), 
heat shock proteins (HSP) and ribosomal proteins identified by IP-only (Red) and 
IP-PolyMAC (Blue) strategies. (A) At the protein level, the protein number of identified 
ribosomal proteins was significantly reduced from 40 in IP-only to 7 in IP-PolyMAC. 
(B)At the peptide level, the peptide number from keratin, HSP and ribosomal proteins 





Figure 2.8 Western blotting analysis of the myc-PRMT5 overexpression in LnCap 
cells. Mouse myc-tag antibody was used for detecting the myc-PRMT5, and the rabbit 
PRMT5 antibody was used for detecting both myc-PRMT5 and endogenous PRMT5. 






Figure 2.9 Western blotting analysis of the myc-PRMT5 affinity purification with 
series elution conditions. LnCap cells overexpressing myc-PRMT5 was precipitated 
with anti-myc antibody and protein G agarose beads. The bait protein was visualized by 
Western blot against mouse anti-myc antibody. The myc-PRMT5 complex was eluted by 
a series of buffer -- 100mM TEA, pH11.6 (E1), 1% TFA (E2) and 2.5x LDS sample 





Figure 2.10 Western blotting analysis of the myc-PRMT5 affinity purification. Ten 
percent of the total lysate (Input) and 30% of IP elution by SDS sample buffer were 
loaded into gel. Blotting was against mouse myc-Tag mAb and rabbit anti-GAPDH 






Figure 2.11 Venn diagram of identified proteins in MS analysis by conventional IP 
(IP-only) and IP-PolyMAC strategies. The known PRMT5 interacting proteins are 
listed. The number does not include those identified in negative controls. H2A, histone 
H2A; H3, histone H3; H4, histone H4; sm D1-D3, small nuclear ribonucleoprotein Sm 
D1- D3; SNRPE, small nuclear ribonucleoprotein E; NFkB, nuclear factor NF-kappa-B; 
HSP90A, HSP90B and HSP90B2, heat shock protein 90 alpha, beta and beta-2; PRMT5, 






Figure 2.12 Motif analysis of the 14 known Plk1 substrate in IP-PolyMAC for 
polo-box binding domain specificity: the distribution of amino acid residue is depicted 







Table 2.1 Known Plk1 interacting proteins in IP-only and IP-PolyMAC 
Known interacting proteins in IP-PolyMAC 
BUB1b [33] 
PRC1 [34] 













Known interacting proteins in IP-only 
Protein name Reference 
MCM7 [41] 
14-3-3 [54] 
Vimentin [55, 56] 
 
Abbreviations: BUB1b, mitotic checkpoint serine/threonine-protein kinase BUB1 beta; 
PRC1, protein regulator of cytokinesis1; FOXO1, forkhead box protein O1; CDK1, 
cyclin-dependent kinase 1; MLF1IP, centromere protein U; FOXM1, forkhead box 
protein M1; RanGAP1, ran GTPase-activating protein 1; WEE1, Wee1-like protein 
kinase; MCM2, DNA replication licensing factor MCM2; SLX4, structure-specific 
endonuclease subunit SLX4; ERCC6L, DNA excision repair protein ERCC-6-like; 
HSP90, heat shock protein 90; GWL, serine/threonine-protein kinase greatwall; P53BP, 





Table 2.2 PRMT5 interacting candidates identified in IP-PolyMAC 
 
Accession Phosphopeptides Description 
G3V5W5 VSSGRDLNCVPEIADT
LGAVAK 
Protein arginine N-methyltransferase 5  
H0YDD8 KEESEESDDDMGFGLF
D 
60S acidic ribosomal protein P2  
B4DYL6 ASGQVMALKMNTLSS
NRANMLK 
cDNA FLJ58888, highly similar to dual 
specificity testis-specific protein kinase 2 
E9PJF4 FEEESKEPVADEEEED
SDDDVEPITEFR 
Methylosome subunit pICln   
B7Z1H6 GVVPNTRRMVLTLPS
GAVC 
cDNA FLJ52121, highly similar to 
Fructose-bisphosphate aldolase C 
P55851 YMNSALGQYSSAGHC
ALTMLQKEGPR 
Mitochondrial uncoupling protein 2 
B7Z6T4 MVPKGATMLVIPPGLS
EEEEALQK 
cDNA FLJ56180, highly similar to negative 
elongation factor E 
Q9H1E3 NSQEDSEDSEDKDVK Nuclear ubiquitous casein and 
cyclin-dependent kinase substrate 1 
B7Z918 GRPVPMMIPDELAPTY
SLDTR 





Isoform 3 of Krueppel-like factor 4 








PR domain zinc finger protein 15 
P38570 YHSLPIIIKGSVGGLLV
LIVILVILFK 











Table 2.2 Continued 
 
Accession Phosphopeptides Description 
IPI00477734.2 TTEDLSFK 15 kDa protein 
IPI00793191.1 MQNLNDSLVSYLDK 14 kDa protein 
IPI00936437.2 TQSADWLRVSVPIGQSP
K 
hypothetical protein LOC100287063 
Q14520 N/A Hyaluronan-binding protein 2  
Q96GX5 N/A Serine/threonine-protein kinase greatwall 
H0YBY6 N/A Disks large-associated protein 2 (Fragment)  
Q86X95 N/A Corepressor interacting with RBPJ 1  
Q86WV7 N/A CCDC43 protein 
E9PN89 N/A Heat shock cognate 71 kDa protein 
(Fragment) 
Q6ZNW8 N/A  CDNA FLJ26989 fis, clone SLV03395 
IPI00976333.1 N/A  Novel protein (SAMD) 
P10636 N/A  microtubule-associated protein tau isoform 1 
H0YCA0 N/A Cullin-5 (Fragment) 
 




Table 2.3 Plk1 and PRMT5 selected candidates for future investigation 
 
PLK1 complex 
Protein name Site of phosphoprylation 
Stathmin RAsGQAFELILsPR S16, S25 
NFkB IGELGAPEVWGLsPK S149 
MRE11A NYSEVIEVDEsDVEEDIFPTTSK S493 
HMGA KLEKEEEEGISQESSEEEQ S91, S92 
ACAA KDGTVTAGNASGVADGAGAVIIASEDAVKK T244, 
T246, 
S251 
MDC1 LLLAEDSEEEVDFLSER S168 
PRKAR2A VADAKGDSESEEDEDLEVPVPSR S78, S80 
EIF5B VEMYSGSDDDDDFNKLPK Y134, 
S135, 
S137 
FOXO1 ASLQSGQEGAGDSPGSQFSK S261 
PRMT5 complex 
Protein name Site of phosphoprylation 
UPC2 YMNSALGQYSSAGHCALTMLQKEGPR S251, 
S252, 
T259 





Abbreviations: NFkB, NF-kappa-B-activating protein; MRE11A, isoform 2 of 
Double-strand break repair protein MRE11A; HMGA, isoform HMG-Y of High 
mobility group protein HMG-I/HMG-Y; EIF5B, eukaryotic translation initiation 
factor 5B; MDC1, Mediator of DNA damage checkpoint 1; ACAA, 
3-ketoacyl-CoA thiolase, mitochondrial; PRKAR2A, protein kinase, 
cAMP-dependent, regulatory, type II, alpha, isoform CRA_b; FOXO1, Forkhead 
box protein O1. 
 
Lower case of S, T, and Y = identified phosphorylation sites in this study 
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3.1.1 Host-Virus interactome study 
    Viruses have rapid replication cycle and genomic variants in hosts which cause 
serious problems in humans, agriculture and livestock. The properties of rapid mutation 
and recombination to adopt the host environment lead to a complex epidemiology. 
Currently, several genomics and proteomics approaches are used to study virus-host 
interactions, particularly since the rapid accumulation of sequence database. 
High-throughput genome-wide RNAi screening has been used for studying the host 
factors required for replication of Influenza A virus [1, 2], Dengue virus [3] and human 
HIV [4]. The proteomics tools including two-dimensional differential in-gel 
electrophoresis (2-D DIGE), MALDI-MS/MS and LC-MS/MS combined with 
quantitative methods have been used to reveal the physical interaction between virus and 
host cells, and to monitor the dynamic cellular proteome responses during the infection 
[5-7]. The above studies have expanded the knowledge of host response to virus infection; 
however, the progress of proteomics studies has lagged behind the genomics-wide studies 
because of the complexity of the cellular proteome. But using the genome-wide approach, 
the mRNA levels cannot fully represent the levels of protein synthesis or the 
posttranslational modifications on proteins which are related to the interaction network. 
Thus, high- throughput virus-host interactome studies by proteomic approaches still have 




3.1.2 Sindbis virus 
    Alphaviruses are a group of enveloped viruses which are emerging pathogens that 
cause human diseases [8]. The symptoms of pathogenic alphaviruses are fever, rash, 
arthritis and encephalitis [9]. Alphaviruses represent a new threat for global infection and 
transmission [10], but the host molecules which are involved in the infection process are 
still obscure. Sindbis virus is a prototypical member of the genus that has been 
engineered for heterologous gene expression [11]. Sindbis virus is important for vaccine 
development due to the high-level expression of heterologous protein per cell and the 
broad range of hosts from mosquitoes to vertebrates [12]. There are four structural 
proteins, E1 (47KDa), E2 (46KDa), 6K and capsid proteins (29KDa), and four 
non-structure proteins in Sindbis virus. The 240 copies of E1 and E2 are arranged as 
E1-E2 heterodimer which is embedded in a host plasma membrane-derived lipid bilayer, 
and the 240 copies of capsid protein with one copy of genomic RNA form the 
nucleocapsid core (NC) in the icosahedral symmetry [13]. E2 and E1 are integral 
membrane proteins, with E2 functioning as the host receptor interactor [14], and E1 is 
required for virus entry by a pH-dependent fusogenic property [15].  
    Because of the prototypical property and vaccine development application, the 
Sindbis virus is the ideal model for us to study the early point of infection by chemical 
modification of the surface proteins. We propose to tag the E1 or E2 proteins with a 
trifunctional reagent for labeling, capturing, and crosslinking its target, and study the 
interaction between virus and host factors at the early entry stage.  
 
3.1.3 Aspect of virology by chemical modification 
The two glycoproteins of E1 and E2 on Sindbis virus have been previously used for 
structure characterization by NHS-Biotin reagent [16]. The biotinylation of only one E1 
lysine residue along with seven E2 lysine residues indicated that E1 protein is buried by 
E2 protein. Moreover, the E1 and E2 cysteine residues were labeled with iodoacetamide 
to study how the disulfide bonds between the two structure proteins help maintain the 
virus integrity [17]. Different Cys residues contained free sulfhydryl groups were labeled 
at pH8.0 or pH 5.3 which means the virus surface structure will change at different pH 
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environments. Here, we used a trifunctional reagent containing three moieties – a 
maleimide group to bind cysteine residues containing free thiols, either a TAMRA 
fluorescence molecule or a photoreactive crosslinker, and a biotin tag for capturing the 
virus particle. The first generation reagent that we called Maleimide-TAMRA-Biotin 
(MTB) probe is shown in Figure 3.1A. The included TAMRA molecule is a rhodamine 
derivative fluorophore with Abs λmax of 557 nm and Em λmax of 583 nm. Maleimide 
can react with the cysteine residues to a stable carbon-sulfur bond. We hypothesized that 
the free thiols on Sindbis virus surface proteins would be the targets for us to label with 
the MTB reagent. TAMRA serves as a fluorescent beacon that can detect the labeled 
proteins after SDS-PAGE with a fluorescence imager. The MTB reagent was used as a 
testing control of the experimental design, including the working ratio of reagent to virus 
particles, the value of Multiplicity Of Infection (MOI), and the biotin capturing test. The 
second generation reagent is Maleimide-LC-SDA-Biotin (MDB) which uses a 
photocrosslinker instead of TAMRA group to crosslink proteins interacting with the virus 
(Figure 3.1B). The photocrosslinker of diazirine can be activated by UV irradiation and 
creates reactive carbine intermediate that can form covalent bonds through addition 
reaction with any amino acid side chain or peptide backbone within the spacer arm 
distance [18]. Thus, after crosslinking, we can use harsh wash conditions to remove most 
of the non-specific binding proteins. In this thesis, we only discuss the method 




3.2 Materials and Methods 
 
3.2.1 Cell culture and virus purification 
Wt-Sindbis viruses (Toto64) were propagated in baby hamster kidney (BHK) cells 
which were grown in MEM with 10% fetal bovine serum at 37°C and 5% CO2. Twenty 
150mm culture dishes of 80% confluence BHK cells were infected at a multiplicity of 
infection (MOI) of 10 Plaque Forming Unit (PFU)/cell and harvested 24 hour 
post-infection. The harvested supernatant was centrifuged in a JA-14 Beckman rotor at 
10,000 rpm for 20 min to remove cell debris from the solution. The supernatant was 
loaded on top of 2 ml of 30% sucrose solution in PBS and centrifuged in Ti 50.2 rotor at 
32,000 rpm for 2 hours at 4°C. After centrifugation, the supernatant was discarded and the 
tubes placed on rotating table for 15 min. The virus solution was collected from the 
bottom of tubes. The medium solution was replaced with sterile PBS by Ultrafree-4 
centrifugal filter unit (100KDa, 4ml, Millipore). The virus solution was split into small 
aliquots and stored at -80°C. 
 
3.2.2 Plaque assay 
Serial dilutions (10-fold) of virus were prepared in PBS containing 1% FBS plus 10 
mM CaCl2 and 10 mM MgCl2. BHK cells were seeded in 6-well plates until 90% 
confluence and propagated with 250μl of dilutions at room temperature for 1 hour. Then 
MEM containing 5% FBS and 1% agarose was added. Cells were incubated at 37°C for 
48 hours and the plaques were stained with neural red in PBS.    
 
3.2.3 Maleimide-TAMRA-Biotin (MTB) reagent labeling 
10
9
 PFU/ml Sindbis virus in PBS, pH7.4 were adjusted to pH6 by slightly acidic 
sterile PBS. Labeling of the virus was done with 1mM MTB reagent at 4°C overnight, 
and the free reagent was removed by Zeba spin desalting columns, 7K MW (Thermo 




3.2.4 Western blotting 
The labeled Sindbis virus particles were separated by SDS-PAGE and transferred 
onto two PVDF membranes. Membrane was incubated in blocking buffer (10% BSA in 
TBS with 0.05% Tween-20) for 1 h at room temperature and then incubated in blocking 
buffer containing the 1:1000 dilution of avidin-horseradish peroxidase (HRP) at room 
temperature for 1 hour or 1:500 dilution of mouse anti-E1-161 antibody (Gift from Dr. 
Kuhn’s lab) at 4°C overnight. The membranes were then washed three times in TBS with 
0.05% Tween-20 for 5min. The membrane incubated with avidin-HRP was directly 
developed with HyGlo chemiluminescence reagent (Denville scientific, Metuchen, NJ). 
The membrane containing the anti-E1-161 antibody was further incubated with 
horseradish peroxidase-conjugated anti-mouse IgG antibody (Cell Signaling 
Technologies) for 1 hour at room temperature. After several washes, the blot was 
developed with HyGlo chemiluminescence reagent (Denville scientific, Metuchen, NJ). 
 
3.2.5 BHK cells infection of MTB-labeled Sindbis virus  
BHK cells in a 10 cm culture dish were infected with wt-SINV (Toto64) or 
MTB-labeled SINV at MOI 15. First, the culture medium was discarded and the cells 
washed with sterile PBS. Virus solution in 3ml of MEM was overlaid on the cells and 
incubated on rocking platform at room temperature for 1 hour (the time needed for 
viruses attach onto the cell surface). MEM containing 1% FBS was added into each plate 
and incubated at 37°C for 1 hour (the time needed for viruses enter into cells). Finally, 
infected cells were harvested by trypsin and washed with sterile PBS. The cell pellet was 
stored at -80°C until future use.  
 
3.2.6 Cell lysis, streptavidin agarose capture, trypsin digestion and Nu-Tip®  C18 
desalting 
Cell pellet was resuspended in lysis buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
1% NP40] supplemented with 1x protease inhibitor (Tablet from Roche). Cells were 
lysed by probe sonication on ice twice with a 20 second pulse and 10 second interval. 
The supernatant containing soluble proteins was collected after centrifugation at 14000 
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rpm for 10 minus. MTB-labeled SINV viruses were captured by Pierce
®
 Streptavidin 
agarose (Thermo Scientific) and further washed with lysis buffer. The virus-protein 
complex was reduced in 50 mM ammonium bicarbonate containing 5 mM dithiothreitol 
for 30 minus at 50 °C. The proteins were further alkylated in 15 mM iodoacetamide for 1 
hour in the dark at room temperature and digested with 0.5 μg proteomics grade trypsin 
(Sigma) in a total volume of 200 μl solution containing 50 mM ammonium bicarbonate 
(pH 8.3) at 37℃ overnight. The tryptic peptides solution was acidified by Trifluoroacetic 
acid (TFA). The Nu-Tip®  C18 (Glygen Corp.) were prewetted by pipetting three times 
with 100% Acetonitrile (ACN). The tips were equilibrated by pipetting ten times with 
0.1% TFA. The peptides were bound to Nu-Tip by fully pipetting to a dead stop and 
aspirating sample 20 cycles, and then washed tips with 0.1% TFA for 15 cycles. Fifty 
microliters of 0.1%TFA/80% ACN were aspirated into a new sterile centrifuge tubes and 
pipetted 20 times to elute peptides. The desalting peptides were dried by speedvac.   
 
3.2.7 Mass spectrometry 
The resulting peptides were resuspended in a solution containing 0.25% formic acid 
(v/v) and analyzed using an Easy-nLC1000 (Thermo Scientific, San Jose, CA) coupled to a 
hybrid mass spectrometer (LTQ-Orbitrap-Velos; Thermo Scientific, San Jose, CA). The 
peptides were applied to an analytical column (75 μ m x 30 cm, 2.2 μ m, 
ProntoPEARL-120-2.2-C18AQ beads (BISCHOFF chromatography) at ~200 nl/min, and 
eluted using a gradient that ran from 5 to 30% of acetonitrile (0.1% formic acid) over 90 
minutes. The LTQ-Orbitrap-Velos MS was operated in a data-dependent mode to switch 
between MS and MS2 acquisitions. The MS survey scans were acquired over a full m/z 
range of 300-2000 by the detector. The 20 most intense precursor ions were sequentially 
isolated and subjected to collision induced dissociation (CID) in the linear ion trap. The 
general mass spectrometric conditions were: ESI voltage - 2.8 kV; transfer capillary 






3.2.8 Computational analysis of mass spectra 
The Excalibur MS raw files were searched against a mixed database containing 
mouse plus Sindbis virus using SEQUEST algorithm on Proteome Discoverer (version 
1.3, Thermo Scientific). The search parameters included a peptide mass tolerance of 10 
ppm and the MS/MS tolerance of 0.8 Da. In the residues modification, the variable 
modifications were set to +15.9949Da for the potential oxidation of methionine. The 
static modification of cysteine residues of +57.0214Da was set due to the alkylation by 
iodoacetamide. Searches were performed with full tryptic digestion and allowed a 
maximum of two missed cleavages on the peptides. False discovery rates (FDR) were set 






3.3.1 Analysis of the working labeling ratio of Maleimide-TAMRA-Biotin (MTB) 
reagent to Sindbis virus (SINV) 
    In order to determine whether the MTB-labeled SINV would maintain the viral 
infectivity, we incubated different concentrations of MTB reagent with purified virus 
particles. The concentration of MTB reagent was increased from 0.01 μM to a maximum 
of 10mM MTB reagent. The negative control was the batch of viral particles without 
labeling. Plaque assay was performed using each labeled virus sample to determine the 
viral titer (Plaque Forming Unit/ml). The effect of virus labeling is shown in Figure 3.2. 
The plot demonstrates that the infectivity was unaffected at the concentration of below 
1mM MTB reagent label. With increased concentration beyond that point, the infectivity 
significantly dropped by three orders of magnitude. In order to get the highest labeling 
efficiency without affecting the virus pathogenic property, we have selected a range of 
1mM to 5mM MTB reagent to test the labeling efficiency. The labeling result was first 
tested by detecting the TAMRA fluorescence in gel (Figure 3.3). According to the gel 
image, the fluorescence intensity appears darker after increasing the MTB labeling 
concentration (Figure 3.3A). The same gel was stained by Coomassie Brilliant Blue and 
showed equal amount of sample loading (Figure 3.3B). The infectivity analysis of the 
five labeled virus samples was also performed by plaque assay (Figure 3.4). The plot 
shows that the infectivity is unaffected up to MTB concentration of 2 mM. At 1mM of 
MTB reagent, the infectivity is slightly reduced but still at the similar level with 
non-labeled virus (0mM, negative control). Thus, the MTB reagent concentration for 
each ~ 10
9
 PFU SINV labeling was determined to be 1mM.  
 
3.3.2 Analysis of the SINV labeling specificity by avidin and anti - SINV structure 
protein antibody 
    The labeling of SINV by the 1mM MTB reagent was further tested for labeling 
specificity by western blotting with avidin-HRP and the anti-E1 structure protein 
antibody (E1-161, a gift from Kuhn lab). Since the labeled sites are supposed to occur on 
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the virus surface, we expect that E1 and E2 virus surface structure proteins can be 
detected at MW ~ 50KDa. In Figure 3.5, the blot against avidin-HRP shows a pattern of 
multiple bands. In order to verify which bands correspond to E1/E2 proteins, we used 
anti-E1 antibody to do the comparison. The E1 band is observed around the expected 50 
kDa in both of MTB-labeled virus and unlabeled virus (negative control). In the 
avidin-HRP blot, the 50kDa region also produced the second major detectable band 
(Figure 3.5; indicated by red arrow). Due to the procedure of virus purification, some 
of the proteins from culture medium, such as serum albumin, could be the detected 
nonspecific non-virus contaminants. In our attempts to remove these, even the use of 
100kDa MW cut-off spin column to remove the non-virus molecules still resulted in 
detectable media proteins  
 
3.3.3 Examination of capture efficiency of MTB-labeled SINV by streptavidin beads 
    One millimolar [mM] of MTB reagent has been determined as the working 
concentration to label a batch of 10
9
 PFU SINV, and the labeling efficiency has been 
examined by western blotting using avidin-HRP and anti-E1 antibody (Figure 3.5). The 
next logical step was the test of whether the labeled virus could be captured by 
streptavidin agarose beads. After the labeling, we removed the free MTB reagent which 
may interfere with the binding of MTB-labeled virus to streptavidin beads by Zeba 
column (7kDa MW cut-off spin column) and dialysis. As demonstrated in Figure 3.6, the 
sample eluted by boiling in SDS buffer showed an obvious TAMRA fluorescent band at 
~50kDa. A light smear above the bands is likely due to different degrees of MTB 
modification on E1/E2 proteins.  
 
3.3.4 MS analysis of MTB labeled SINV infection 
We first carried out an in vitro test to determine the optimal Multiplicity of Infection 
(MOI), before the complete infection test. For this purpose, we mixed the BHK cells with 
MTB-labeled SINV at MOI 5 and 15, lysed the mixture and captured the MTB-labeled 
virus by streptavidin agarose beads. Non-labeled virus was used as a negative control. 
The captured proteins were reduced and alkylated on the beads with 5mM DTT and 
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15mM IAA, respectively. Trypsin was added for on-beads digestion. Tryptic peptides 
were collected, desalted with C18 tips and analyzed by LC-MS. As shown in Table 3.1, 
there were 968 mouse proteins with two Sindbis virus proteins (Capsid and E2 protein) 
identified from the mixture at MOI 15. Only one Sindbis virus capsid and a total of 924 
proteins were identified from the mixture at MOI 5. Only virus capsid was present in the 
negative control at MOI 5, which we consider as a non-specific identification. Thus, MOI 
15 was determined to be the minimum MOI value for future infection.   
For the complete infection test, labeled virus was used to infect the BHK cells at 
MOI 15 for 45 minute at 37°C. The cells were similarly harvested, lysed and captured 
onto streptavidin agarose beads. There were 557 total proteins with one virus E1-E2 
heterodimer identified by the LC-MS/MS analysis (Table 3.2). Six peptides correspond 
to the E1-E2 heterodimer in the list, which increases the likelihood of accurate virus 
protein identification. As the result of these optimization efforts, the 1mM MTB- labeled 
virus retains similar infectivity of BHK cells to that of unlabeled virus, and can be 






3.4.1 The trifunctional reagent provides an efficient way to modify model virus for 
virus-host early entry study 
We used the Maleimide-TAMRA-Biotin (MTB) reagent to successfully modify the 
surface structure proteins of Sindbis virus. After the removal of protein identified in the 
negative control, there were 199 proteins identified post-infection by LC-MS/MS 
analysis. Those proteins were further classified by Ingenuity Pathway Analysis (IPA; 
http://www.ingenuity.com/products/ipa). Since our study is focused on the early entry 
stage of the virus, the infection time was limited to only 45 minutes. We identified 
several proteins known to be involved in the pathway of virus entry. For instance, the 
proteins involved in clathrin-mediated endocytosis signaling are transferrin receptor, 
integrin, actin-related proteins (ACTR2, ACTR3, ARPC1B and ARPC4), transporter 
proteins (AP2M1 and AP2A1) and SH3GLB1, which is an enzyme involved in 
endocytosis. Proteins in caveolar-mediated endocytosis signaling, integrin signaling, and 
FcƳ receptor-mediated phagocytosis in macrophages and monocytes were also identified 
in the list. When we look into the disease and bio-functions category, there were 40 
proteins identified that related to the viral infection, such as transferrin receptor (TFRC), 
which have been reported to help the virus entry by endocytic pathway [19]. Moreover, 
the identified protein PML plays a role in antiviral defense mechanism [20], and KPBN1 
functions as the HIV integration factor [4]. Thus, we conclude that the 1mM 
MTB-labeled Sindbis virus can truly offer a detailed examination of the infection 
processes of BHK cells.   
 
3.4.2 The limitation of virus identification 
According to the previous studies, we hypothesized that virus surface proteins were 
ideal targets of chemical modification for the virus early entry study. More identification 
number of virus peptides provides higher confidence for the successful capturing 
condition. Our analysis identified six E1-E2 heterodimer peptides in the MS list. We tried 
to increase the virus peptides identification number by utilizing harsher lysis conditions 
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(such as 8M Urea or 2% SDS). The harsher lysis conditions were used to denature the 
virus structure more completely and we supposed that the denatured viruses can be 
digested by trypsin more efficiently. However, the tested conditions were not successful 
in increasing the peptides identification number. The MTB labeling may cause some 
disruption during trypsin digestion. It is possible that MTB labeling covered multiple 
tryptic sites, thus resulting in limited tryptic peptides identification. Increasing the MOI 
of infection or modifying the structure of the reagent (e.g. spacer arm length) might be 
the solutions.  
 
3.4.3 Future direction 
In this study, we identified 556 BHK cell proteins with one Sindbis virus structure 
protein in the MTB-labeled virus sample. Even we identified several proteins which were 
related to the virus infection pathways, the optimal result we expected was not with this 
high number of proteins identification. There are 358 BHK proteins overlapped with 
non-labeled control sample which means the non-specific capturing is high. The reason 
may cause by the non-specific binding on the agarose beads. MTB is the first generation 
reagent that we used for tracing the labeling efficiency by TAMRA fluorescence. In order 
to address the problem of non-specific protein binding, the next generation of our 
trifunctional reagent substitutes the TAMRA group with an NHS-Diazirine (SDA) 
crosslinker. The UV-activated photocrosslinker targets specific amino acid groups (e.g., 
lysine or cysteine) at the correct distance to capture virus and host protein interactions 
[21]. After activating the photocrosslinker to “fix” the interactome, any virus binding 
partners can be retained even after several harsh wash conditions to remove the 
nonspecific binding proteins. Such an approach should result in more accurate 
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Figure 3.1 Maleimide-TAMRA-Biotin (MTB) and Maleimide- LC-SDA-Biotin 
(MDB) reagents. The two trifunctional reagents used for Sindbis virus modification 
contain a maleimide moiety for coupling to ligands via free thiol group on cysteine 
residues, a biotin group for affinity purification, and rather A) TAMRA fluorophore for 
tracing the labeling efficiency or B) photocrosslinker of diazirine for virus-host 






Figure 3.2 Plot of the plaque forming units (PFU) of MTB labeled Sindbis virus. 
X-axis indicates the concentration of MTB reagent. The unlabeled Sindbis virus serves as 
a control (Green spot). The range indicated by red oval was chosen for further 






Figure 3.3 Analysis of Maleimide-TAMRA-Biotin (MTB) reagent labeling efficiency 
by gel image. Sindbis virus were labeled by 0mM (Control), 1, 2, 3, 4 and 5mM of MTB 
reagent and loaded onto SDS-PAGE. (A) TAMRA fluorescence signal was visualized by 







Figure 3.4 Plot of the plaque forming units (PFU) of 0-5mM MTB labeled Sindbis 
virus. BHK cells seeded in 6-well plates were infected with MTB-labeled Sindbis virus 
and incubated with 1% agar medium for 2 days at 37°C, 5% CO2. The plaques were 
stained by neural red for 4 hours and counted for virus amount released into the medium. 
X-axis indicates the concentration of MTB reagent. “Fresh” indicates the original viral 






Figure 3.5 Western blotting analysis of the MTB labeled Sindbis virus. Sindbis virus 
was labeled by 1mM MTB reagent at 4°C overnight and the labeled proteins examined by 
Western Blot using avidin-HRP and sindbis virus anti-E1 antibody (E1-161). Unlabeled 
virus serves as a negative control. Virus E1 protein was detected by Western Blot against 
E1 protein around the predicted molecular weight of 50kDa. The likely virus E1/E2 
proteins are indicated by the red arrow on the membrane blotted using avidin-HRP. The 







Figure 3.6 Gel image of TAMRA fluorescence signal after MTB-labeled Sindbis 
virus were captured by streptavidin beads. Sindbis virus was labeled by 1mM MTB 
reagent and captured with streptavidin agarose beads. The captured virus was eluted by 
boiling in SDS sample buffer and visualized for TAMRA fluorescence with Typhoon 
imager. 1% of total input volume and flowthrough (FT), as well as 100% of elution were 






Table 3.1 LC-MS/MS analysis summary of the in vitro streptavidin-captured 





Table 3.2 LC-MS analysis summary of the streptavidin-captured Sindbis virus 
proteins and peptides after complete in situ infection 
 
 
